Utility and safety of bevacizumab in patients with metastatic breast cancer
- At: 2012 FIP Congress in Amsterdam (the Netherlands)
- Type: Poster
- By: HSU, Pei-Chun (Changhua Christian Hospital, Pharmacy, Changhua, China Taiwan)
- Co-author(s): Ng, S.P. (Changhua Christian Hospital, Changhua, China Taiwan)
Chien, S.Y. (Changhua Christian Hospital, Changhua, China Taiwan)
: Bevacizumab is used as first-line therapy for HER2-negative metastatic breast cancer with significant improvement in progression-free survival. But the indication was withdrawn by FDA due to increased risks of cardiovascular disease and fatal hemorrhage at June, 2011. Here we conducted this study to evaluate the utility and side The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress.